# Belumosudil Mesylate (Rezurock)

Source: https://ourhealthnetwork.com/drugs/belumosudil-mesylate
Data: FDA Orange Book and OpenFDA, refreshed periodically

## What is Belumosudil Mesylate?

Belumosudil Mesylate (brand name: Rezurock) is a kinase inhibitor. It is prescribed to treat graft vs host disease. Across the United States, 199 doctors prescribe Belumosudil to approximately 141 Medicare patients.

## Brand names

Rezurock

## Indications

Belumosudil Mesylate is primarily prescribed for the treatment of graft vs host disease.

## Conditions treated

- [Graft vs Host Disease](https://ourhealthnetwork.com/conditions/graft-vs-host-disease)

## Mechanism of action

Belumosudil is an inhibitor of rho-associated, coiled-coil containing protein kinase (ROCK) which inhibits ROCK2 and ROCK1 with IC 50 values of approximately 100 nM and 3 µM, respectively. Belumosudil down-regulated proinflammatory responses via regulation of STAT3/STAT5 phosphorylation and shifting Th17/Treg balance in ex-vivo or in vitro -human T cell assays.

## Drug classification

- Established Pharmacologic Class: kinase inhibitors
- Route of administration: ORAL

## Common side effects

diarrhea, of patients included nausea, were infections

## Sources and disclaimers

- FDA Orange Book and OpenFDA dataset
- This information is for educational purposes only and does not constitute medical advice. Always consult a healthcare professional before starting, stopping, or changing any medication.

## Related

- [All drugs](https://ourhealthnetwork.com/drugs)
- [Find specialists who prescribe this drug](https://ourhealthnetwork.com/find-doctors)
- [Methodology](https://ourhealthnetwork.com/methodology)